What Wegovy actually costs, in plain language

What this guide covers

What Wegovy (semaglutide) costs with and without insurance, why weight coverage is the hard part, the manufacturer self-pay price, and how to find your real number. A calm map of the money side, with no stake in any of it. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The honest disclaimer first. Drug prices in the United States move constantly, programs open and close, and what you pay for Wegovy depends on your insurance, your indication, and the channel you buy through. Everything below is accurate as of July 2026 and framed in ranges for exactly that reason. Treat this page as a map of the system, then verify the current number for your situation with your pharmacy, your plan, and the manufacturer's own pricing pages. Peptips takes no money from drug makers, pharmacies, or telehealth sellers, so nothing here is steering you toward a buying path. If you are still deciding what Wegovy even is, our what is Wegovy guide covers the basics first.
• The list price, and why almost nobody pays it. Wegovy is semaglutide (Ozempic, Wegovy), made by Novo Nordisk, and its U.S. list price for the once-weekly pens has sat above one thousand dollars for a month's supply, broadly in line with the rest of the branded GLP-1 class. The list price is the sticker on the system, the starting point for negotiations between the manufacturer, insurers, and pharmacy middlemen. Most people pay something very different: a copay if insurance covers it, a manufacturer self-pay price if it does not, or a program price if they qualify. The useful question is never what does it list for, it is what would I pay through each door I can actually walk through.
• Door one: insurance, and why weight coverage is the hard part. Coverage follows the indication, and this is where Wegovy differs from its diabetes-labeled sibling Ozempic. Wegovy carries the chronic weight management approval (plus a cardiovascular risk-reduction approval based on the SELECT trial), and many employer plans and state programs still exclude or restrict anti-obesity medication as a category, though that has been shifting year by year. When a plan does cover it, you pay your plan's copay, and commercially insured patients have at times been able to use a manufacturer savings card on top. The cardiovascular indication can sometimes change the coverage picture, which is worth raising with your prescriber. The only reliable way to know is to ask your plan about Wegovy for your specific diagnosis.
• Door two: the manufacturer self-pay price. Novo Nordisk sells Wegovy directly to self-pay patients through its NovoCare Pharmacy channel, at a flat monthly self-pay price that launched well below the pen list price for people paying cash without insurance coverage. In late 2025 the manufacturers also reached federal pricing agreements expected to push some direct-purchase prices further down during 2026. The honest summary: if your insurance says no, the manufacturer self-pay price is the number to check first, and it has generally been moving in the patient's favor. Because Wegovy and Ozempic are the same molecule at different doses, the cost conversation rhymes with the Ozempic cost picture, just under a different label and indication.
• The door we would skip: compounded semaglutide. During the shortage years, compounded semaglutide from pharmacies and telehealth sellers was often the cheapest door. The FDA's position is worth knowing: compounded versions are not FDA-approved, the agency has warned about dosing errors and unverified ingredients, and once the shortage was declared resolved, the legal basis for mass-compounding copies largely ended. With a manufacturer self-pay price now well below the old pen list price, the gap that made compounding tempting has narrowed. We do not link to or take money from any seller in this space, and our honest read is that the approved product through a legitimate channel is the option your prescriber can actually stand behind.

Frequently asked questions